Aurobindo Pharma has received Establishment Inspection Report for Unit VI-B, classifying the facility as Voluntary Action Indicated (VAI). The U.S. Food and Drug Administration (USFDA) had conducted an inspection at the Unit VI-B, a Formulation manufacturing facility of the Company, situated at Chitkul Village, Patancheru Mandal, Sangareddy District, Telangana, from September 22 to September 29, 2023.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
